Regeneus Ltd (ASX:RGS)
Regeneus (ASX:RGS) is a Sydney-based regenerative medicine company developing a portfolio of novel cell-based therapies targeting unmet medical needs in human, with an initial focus on osteoarthritis (OA), neuropathic pain and dermatology. All of the products in the company pipeline are underpinned by proprietary stem cell technologies.
Regenerative medicine is a rapidly advancing interdisciplinary field in healthcare that focuses on repairing and regenerating cells, tissues and organs with the goal to enhance the body’s natural ability to replace or repair tissue damaged or destroyed by injury or disease.
The company's stem cell technologies use mesenchymal stem cells (MSCs) from adipose tissue. MSCs are responsible for promoting the body’s natural healing, by reducing inflammation, promoting tissue repair and reducing scarring. MSCs from adipose tissue are found in much greater numbers than other tissue types (e.g. bone marrow, blood) and are readily available throughout the whole body. The company's stem cell technology platform allows for scalable production of allogeneic cell products for a wide range of therapeutic indications, optimising the licensing prospects for each technology platform. Regeneus has developed technology and protocols for the production of cell secretions from MSCs for the treatment of inflammatory skin conditions (Sygenus).
The company's substantial intellectual property (IP) covers a broad range of clinical indications across our product portfolio, creating value for partnering with larger companies for global commercialisation.